An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Oncology Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2017
At a glance
- Drugs Custirsen (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors OncoGenex Technologies
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jun 2013 Planned end date changed from 1 Apr 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 24 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.